| 000 | 01868 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250513194809.0 | ||
| 264 | 0 | _c19991122 | |
| 008 | 199911s 0 0 eng d | ||
| 022 | _a0004-3591 | ||
| 024 | 7 |
_a10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCohen, S | |
| 245 | 0 | 0 |
_aRisedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. _h[electronic resource] |
| 260 |
_bArthritis and rheumatism _cNov 1999 |
||
| 300 |
_a2309-18 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xadverse effects |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 | _aBiomarkers |
| 650 | 0 | 4 |
_aBone Resorption _xchemically induced |
| 650 | 0 | 4 |
_aCalcium Channel Blockers _xadverse effects |
| 650 | 0 | 4 | _aDemography |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEtidronic Acid _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRisedronic Acid |
| 700 | 1 | _aLevy, R M | |
| 700 | 1 | _aKeller, M | |
| 700 | 1 | _aBoling, E | |
| 700 | 1 | _aEmkey, R D | |
| 700 | 1 | _aGreenwald, M | |
| 700 | 1 | _aZizic, T M | |
| 700 | 1 | _aWallach, S | |
| 700 | 1 | _aSewell, K L | |
| 700 | 1 | _aLukert, B P | |
| 700 | 1 | _aAxelrod, D W | |
| 700 | 1 | _aChines, A A | |
| 773 | 0 |
_tArthritis and rheumatism _gvol. 42 _gno. 11 _gp. 2309-18 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K _zAvailable from publisher's website |
| 999 |
_c10511600 _d10511600 |
||